<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39376328</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2231-3796</ISSN><JournalIssue CitedMedium="Print"><Volume>76</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India</Title><ISOAbbreviation>Indian J Otolaryngol Head Neck Surg</ISOAbbreviation></Journal><ArticleTitle>Pre and Post Covid - 19 Experience of the 'Amphotericin Sandwich' Therapy in the Management of Mucormycosis.</ArticleTitle><Pagination><StartPage>4184</StartPage><EndPage>4188</EndPage><MedlinePgn>4184-4188</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12070-024-04812-7</ELocationID><Abstract><AbstractText>Mucormycosis is caused by saprophytic fungi belonging to the species mucorales. The disease commonly affects patients with immunocompromised states such as uncontrolled diabetes, blood disorders and organ transplantation recepients. The usual mode of management is by using antifungals such as amphotericin B and surgery in the form of debridement of the necrotic tissue. A study was conducted on patients of mucormycosis during the pre-Covid-19 and Covid-19 era to evaluate the effectiveness of the Sandwich Therapy of amphotericin B. The mortality rate was found to be 3.57% during the pre- Covid-19 period and 18.8% during the Covid-19 period. This is very low as opposed to 50% quoted by many other studies. The Sandwich Therapy as discussed above for extensive mucormycosis can be useful in curtailing the disease already established to its present location and preventing its further spread either naturally or by the act of debridement per se. It also provides a sustained anti fungal umbrella in the blood to deal with the disease at microscopic level in the blood stream thus reducing mortality.</AbstractText><CopyrightInformation>© Association of Otolaryngologists of India 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Joshi</LastName><ForeName>Samir Vinayak</ForeName><Initials>SV</Initials><AffiliationInfo><Affiliation>K.J.Somaiya Medical College &amp; Research Centre Sion East, Mumbai, Maharashtra 400022 India.</Affiliation><Identifier Source="GRID">grid.465548.e</Identifier><Identifier Source="ISNI">0000 0004 1774 9894</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Havaldar</LastName><ForeName>Rajesh Radhakrishna</ForeName><Initials>RR</Initials><Identifier Source="ORCID">0000-0002-7366-3804</Identifier><AffiliationInfo><Affiliation>Department of ENT &amp; HNS J.N.Medical College, KAHER Belagavi, Belagavi, Karnataka 590010 India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>06</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>Indian J Otolaryngol Head Neck Surg</MedlineTA><NlmUniqueID>9422551</NlmUniqueID><ISSNLinking>2231-3796</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amphotericin B</Keyword><Keyword MajorTopicYN="N">Mucormycosis</Keyword><Keyword MajorTopicYN="N">Sandwich therapy</Keyword></KeywordList><CoiStatement>Competing InterestsNot applicable.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>4</Hour><Minute>35</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39376328</ArticleId><ArticleId IdType="pmc">PMC11456114</ArticleId><ArticleId IdType="doi">10.1007/s12070-024-04812-7</ArticleId><ArticleId IdType="pii">4812</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gomes MZ, Lewis RE, Kontoyiannis DP (2011) Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species. Clin Microbiol Rev 24:411–445. 10.1128/CMR.00056-10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3122490</ArticleId><ArticleId IdType="pubmed">21482731</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon-Chung KJ (2012) Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: molecular mycologic perspectives. Clin Infect Dis 54:S8–S15. 10.1093/cid/cir864</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3276235</ArticleId><ArticleId IdType="pubmed">22247451</ArticleId></ArticleIdList></Reference><Reference><Citation>Skiada A, Pagano L, Groll A, Zimmerli S, Dupont B, Lagrou K, Lass-Florl C, Bouza E, Klimko N, Gaustad P, Richardson M, Hamal P, Akova M, Meis JF, Rodriguez-Tudela JL, Roilides E, Mitrousia-Ziouva A, Petrikkos G, for the European Confederation of Medical Mycology Working Group on Zygomycosis (2011) Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect 17:1859–1867. 10.1111/j.1469-0691.2010.03456.x</Citation><ArticleIdList><ArticleId IdType="pubmed">21199154</ArticleId></ArticleIdList></Reference><Reference><Citation>Roden MM, Zaoutis TE, Buchanan WL et al (2005) Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 41:634–653</Citation><ArticleIdList><ArticleId IdType="pubmed">16080086</ArticleId></ArticleIdList></Reference><Reference><Citation>Spellberg B, Edwards J Jr, Ibrahim A (2005) Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 18:556–569</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1195964</ArticleId><ArticleId IdType="pubmed">16020690</ArticleId></ArticleIdList></Reference><Reference><Citation>Spellberg B, Ibrahim AS (2010) Recent advances in the treatment of mucormycosis. Curr Infect Dis Rep 12(6):423–429. 10.1007/s11908-010-0129-9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2947016</ArticleId><ArticleId IdType="pubmed">21308550</ArticleId></ArticleIdList></Reference><Reference><Citation>Espinel-Ingroff A, Chakrabarti A, Chowdhary A et al (2015) Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of Mucorales. Antimicrob Agents Chemother 59(3):1745–1750. 10.1128/AAC.04435-14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4325796</ArticleId><ArticleId IdType="pubmed">25583714</ArticleId></ArticleIdList></Reference><Reference><Citation>Kontoyiannis DP, Lewis RE (2011) How I treat mucormycosis. Blood 118(5):1216–1224. 10.1182/blood-2011-03-316430</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3292433</ArticleId><ArticleId IdType="pubmed">21622653</ArticleId></ArticleIdList></Reference><Reference><Citation>Walther G, Pawłowska J, Alastruey-Izquierdo A, Wrzosek M, Rodriguez-Tudela JL, Dolatabadi S, Chakrabarti A, de Hoog GS (2013) DNA barcoding in Mucorales: an inventory of biodiversity. Persoonia 30:11–47. 10.3767/003158513X665070</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3734965</ArticleId><ArticleId IdType="pubmed">24027345</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornely OA, Arikan-Akdagli S, Dannaoui E, Groll AH, Lagrou K, Chakrabarti A, Lanternier F, Pagano L, Skiada A, Akova M, Arendrup MC, Boekhout T, Chowdhary A, Cuenca-Estrella M, Freiberger T, Guinea J, Guarro J, de Hoog S, Hope W, Johnson E, Kathuria S, Lackner M, Lass-Florl C, Lortholary O, Meis JF, Meletiadis J, Munoz P, Richardson M, Roilides E, Tortorano AM, Ullmann AJ, van Diepeningen A, Verweij P, Petrikkos G (2014) ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect 20(Suppl 3):5–26. 10.1111/1469-0691.12371</Citation><ArticleIdList><ArticleId IdType="pubmed">24479848</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruping MJ, Heinz WJ, Kindo AJ, Rickerts V, Lass-Florl C, Beisel C, Herbrecht CR, Roth Y, Silling G, Ullmann AJ, Borchert K, Egerer G, Maertens J, Maschmeyer G, Simon A, Wattad M, Fischer G, Vehreschild J, Cornely OA (2010) Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother 65:296–302. 10.1093/jac/dkp430</Citation><ArticleIdList><ArticleId IdType="pubmed">20008047</ArticleId></ArticleIdList></Reference><Reference><Citation>Tissot F, Agrawal S, Pagano L, Petrikkos G, Groll AH, Skiada A, Lass-Florl C, Calandra T, Viscoly C, Herbrecht R (2017) ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopooietic stem cell transplant patients. Haematologica 102:433–444</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5394968</ArticleId><ArticleId IdType="pubmed">28011902</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornely OA, Arikan-Akdagli S, Dannaoui E, Groll AH, Lagrou K, Chakrabarti A, Lanternier F, Pagano L, Skiada A, Akova M et al (2014) ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin. Microbiol. Infect. 2014, 20, 5–26</Citation><ArticleIdList><ArticleId IdType="pubmed">24479848</ArticleId></ArticleIdList></Reference><Reference><Citation>Chamilos G, Lewis RE, Kontoyiannis DP (2008) Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 47:503–509</Citation><ArticleIdList><ArticleId IdType="pubmed">18611163</ArticleId></ArticleIdList></Reference><Reference><Citation>Boelaert JR, de Locht M, Van Cutsem J et al (1993) Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J Clin Invest 91:1979–1986</Citation><ArticleIdList><ArticleId IdType="pmc">PMC288195</ArticleId><ArticleId IdType="pubmed">8486769</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Cutsem J, Boelaert JR (1989) Effects of deferoxamine, feroxamine and iron on experimental mucormycosis (zygomycosis). Kidney Int 36:1061–1068</Citation><ArticleIdList><ArticleId IdType="pubmed">2601256</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibrahim AS, Gebermariam T, Fu Y et al (2007) The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 117:2649–2657</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1957543</ArticleId><ArticleId IdType="pubmed">17786247</ArticleId></ArticleIdList></Reference><Reference><Citation>Caramalho R, Maurer E, Binder U, Araujo R, Dolatabadi S, Lass-Florl C, Lackner M (2015) Etest cannot be recommended for in vitro susceptibility testing of Mucorales. Antimicrob Agents Chemother 59:3663–3665</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4432123</ArticleId><ArticleId IdType="pubmed">25845881</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>